CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

Cancer Immunology Research

Volumn 3, Issue 11, 2015, Pages 1257-1268

  Higuchi, Tomoe ^a   Flies, Dallas B ^a   Marjon, Nicole A ^a   Mantia Smaldone, Gina ^b   Ronner, Lukas ^c   Gimotty, Phyllis A ^d   Adams, Sarah F ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; VELIPARIB; ANTINEOPLASTIC AGENT; BRAP PROTEIN, MOUSE; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; LONG TERM SURVIVAL; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; DEFICIENCY; DOSE RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; T-LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED; UBIQUITIN-PROTEIN LIGASES;

EID: 84955300805     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0044     Document Type: Article

References (50)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. Lavou-e V, Th-edrez A, Leveque J, Foucher F, Henno S, Jauffret V, et al. Immunity of human epithelial ovarian carcinoma: The paradigm of immune suppression in cancer. J Transl Med 2013;11:147.
4. Ai M, Curran MA. Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother 2015;64:885-92.
5. Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997;57:4036-41.
6. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100: 4712-17.
7. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008;105:3005-10.
8. Snyder A, Makarov V,Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
9. Sato E,Olson SH,Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
10. McAlpine JN, Porter H, KobelM, Nelson BH, Prentice LM, Kalloger SE, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 2012;25:740-50.
11. Clarke B, Tinker AV, Lee CH, Subramanian S, Van De Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: Novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;22: 393-402.
12. KobayashiH, Ohno S, Sasaki Y,MatsuuraM.Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep 2013;30:1019-29.
13. Russo A, Calo V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. Crit Rev Oncol Hematol 2009;69:28-44.
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
15. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 2005;434:913-17.
16. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.
17. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61.
18. Kummar S, Fleming GF,Oza AM, Sullivan DM, Gandara DR, Naughton M, et al. Randomized trial of oral cyclophosphamide and veliparib in highgrade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res 2015;21:1574-82.
19. Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 2006;66:8949-53.
20. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91.
21. DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, Swisher EM. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res 2007;5:35-45.
22. Cordero AB, Kwon Y, Hua X, Godwin AK. In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. J Vis Exp 2010;42:e2125.
23. Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol 2011;187:1537-41.
24. Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: The role of NK cells. J Immunol 2001;166:89-94.
25. Grinberg-Bleyer Y, Saadoun D, Baeyens A, Billiard F,Goldstein JD,Gregoire S, et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 2010;120:4558-68.
26. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol 2008;Chapter 14:Unit 14.1.
27. Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985;45:2145-53.
28. Paradis TJ, Floyd E, Burkwit J, Cole SH, Brunson B, Elliott E, et al. The antitumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. Cancer Immunol Immunother 2001;50:125-33.
29. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8 T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A 2011;108:266-71.
30. Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, et al. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNgdependent cell-cycle arrest. Cancer Immunol Res 2015;3:26-36.
31. Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-gamma-and TNFdependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008;118:1398-404.
32. Wall L, Burke F, Barton C, Smyth J, Balkwill F. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 2003; 9:2487-96.
33. Khan S, Burt DJ, Ralph C, Thistlethwaite FC, Hawkins RE, Elkord E. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol 2011;138:85-96.
34. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013;73:6900-12.
35. Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother 2014;63:215-24.
36. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194:950-9.
37. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.
38. Miller CH, Maher SG, Young HA. Clinical use of interferon-gamma. AnnN Y Acad Sci 2009;1182:69-79.
39. Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-99.
40. Goldberg MS, XingD, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticlemediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A 2011;108:745-50.
41. O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol 2014;4:42.
42. Burkle A, Virag L. Poly(ADP-ribose): PARadigms and PARadoxes. Mol Aspects Med 2013;34:1046-65.
43. Bai P, Virag L. Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes. FEBS Lett 2012;586:3771-77.
44. Aredia F, Scovassi AI. Poly(ADP-ribose): A signaling molecule in different paradigms of cell death. Biochem Pharmacol 2014;92:157-63.
45. Andrabi SA, Umanah GK, Chang C, Stevens DA, Karuppagounder SS, Gagne JP, et al. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci U S A 2014; 111:10209-14.
46. Steffen JD, Brody JR, Armen RS, Pascal JM. Structural implications for selective targeting of PARPs. Front Oncol 2013;3:301.
47. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: Making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 2013;3:228.
48. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-99.
49. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 2014;20:2424-32.
50. Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, et al. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1-deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol 2014; 133:584-90.